|Articles|March 15, 2002
- BioPharm International-03-15-2002
- Volume 15
- Issue 3
Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?
Author(s)Jill Wechsler
by Jill Wechsler, pp. 55-57, 60 The industry must ensure that manufacturing systems can produce high quality and consistent therapies, efforts that may lead to comparable "subsequent entry" products.
Advertisement
Articles in this issue
over 23 years ago
Guest Editorial: Warning Letters ? A Symptom?over 23 years ago
The Importance of Freezing on Lyophilization Cycle Developmentover 23 years ago
Business Benefits of Computer Systems Validationover 23 years ago
A System Developer's Approach to ValidationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
2
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
3
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
4
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
5
